4/24
03:30 am
calt
Calliditas Announces Positive NefIgArd Open Label Extension Results [Yahoo! Finance]
Medium
Report
Calliditas Announces Positive NefIgArd Open Label Extension Results [Yahoo! Finance]
4/24
03:30 am
calt
Calliditas Announces Positive NefIgArd Open Label Extension Results
Medium
Report
Calliditas Announces Positive NefIgArd Open Label Extension Results
4/24
03:26 am
calt
Calliditas Announces Positive NefIgArd Open Label Extension Results
Medium
Report
Calliditas Announces Positive NefIgArd Open Label Extension Results
4/18
07:23 am
calt
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 [Yahoo! Finance]
Medium
Report
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 [Yahoo! Finance]
4/18
07:13 am
calt
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Medium
Report
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
4/18
07:10 am
calt
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Medium
Report
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
4/9
07:24 am
calt
Calliditas Therapeutics to Attend Conferences in April
Medium
Report
Calliditas Therapeutics to Attend Conferences in April
4/9
07:22 am
calt
Calliditas Therapeutics to Attend Conferences in April
Medium
Report
Calliditas Therapeutics to Attend Conferences in April
4/8
08:38 am
calt
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Low
Report
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
4/8
08:32 am
calt
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Low
Report
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
4/8
03:24 am
calt
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Low
Report
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
4/8
03:22 am
calt
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Low
Report
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
3/11
09:28 pm
calt
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
Medium
Report
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
3/6
02:38 am
calt
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
Medium
Report
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
3/6
02:34 am
calt
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
Medium
Report
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
3/1
07:44 am
calt
Calliditas Therapeutics to Attend Investor Conferences in March [Yahoo! Finance]
Low
Report
Calliditas Therapeutics to Attend Investor Conferences in March [Yahoo! Finance]
3/1
07:43 am
calt
Calliditas Therapeutics to Attend Investor Conferences in March
Low
Report
Calliditas Therapeutics to Attend Investor Conferences in March
3/1
07:39 am
calt
Calliditas Therapeutics to Attend Investor Conferences in March
Low
Report
Calliditas Therapeutics to Attend Investor Conferences in March
2/23
04:03 am
calt
Travere drug for rare kidney condition recommended for EU approval [Reuters]
Low
Report
Travere drug for rare kidney condition recommended for EU approval [Reuters]
2/22
11:28 am
calt
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/22
09:04 am
calt
Calliditas Therapeutics AB (publ) (NASDAQ: CALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Calliditas Therapeutics AB (publ) (NASDAQ: CALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
2/21
01:50 am
calt
Calliditas Year-end report, January - December 2023 [Yahoo! Finance]
Medium
Report
Calliditas Year-end report, January - December 2023 [Yahoo! Finance]
2/21
01:45 am
calt
Calliditas Year-end report, January - December 2023
Medium
Report
Calliditas Year-end report, January - December 2023
2/21
01:43 am
calt
Calliditas Year-end report, January - December 2023
Medium
Report
Calliditas Year-end report, January - December 2023
2/14
01:17 am
calt
Invitation to the presentation of Calliditas' Year-end report January - December 2023 [Yahoo! Finance]
Low
Report
Invitation to the presentation of Calliditas' Year-end report January - December 2023 [Yahoo! Finance]